Repligen Announces Agreement to Acquire ARTeSYN Biosolutions

Favorable Financial Impact of ARTESYN Biosolutions Acquisition R REPLIGEN 7 Expected to add approximately $33M-$36M of revenue in 2021E Gross margins currently below Repligen corporate average with goal of >50% in 2021 2021 investment focus: commercial integration and commercial pipeline build out Expected to be breakeven on adj. EPS in 2021E, accretive in 2022E Projected revenue synergies of ~$10M over the three-year period starting 2021 ARTeSYN Biosolutions

View entire presentation